NASDAQ:EOLS Evolus (EOLS) Stock Price, News & Analysis $9.27 +0.06 (+0.65%) As of 07/3/2025 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Evolus Stock (NASDAQ:EOLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evolus alerts:Sign Up Key Stats Today's Range$9.11▼$9.2850-Day Range$9.10▼$12.0852-Week Range$8.67▼$17.82Volume424,231 shsAverage Volume754,518 shsMarket Capitalization$597.73 millionP/E RatioN/ADividend YieldN/APrice Target$23.75Consensus RatingBuy Company Overview Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Read More Evolus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreEOLS MarketRank™: Evolus scored higher than 72% of companies evaluated by MarketBeat, and ranked 853rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvolus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvolus has only been the subject of 3 research reports in the past 90 days.Read more about Evolus' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evolus are expected to grow in the coming year, from ($0.61) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evolus is -10.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evolus is -10.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvolus has a P/B Ratio of 103.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Evolus' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.49% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Evolus has recently increased by 9.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvolus does not currently pay a dividend.Dividend GrowthEvolus does not have a long track record of dividend growth. Sustainability and ESG3.5 / 5Environmental Score-1.27 Percentage of Shares Shorted17.49% of the float of Evolus has been sold short.Short Interest Ratio / Days to CoverEvolus has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Evolus has recently increased by 9.72%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for EOLS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Evolus to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Evolus insiders have sold 713.28% more of their company's stock than they have bought. Specifically, they have bought $189,000.00 in company stock and sold $1,537,090.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Evolus is held by insiders.Percentage Held by Institutions90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Evolus' insider trading history. Receive EOLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter. Email Address EOLS Stock News HeadlinesEvolus, Inc. (NASDAQ:EOLS) Director Buys $189,000.00 in StockJune 11, 2025 | insidertrades.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 | businesswire.comElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.July 4 at 2:00 AM | Banyan Hill Publishing (Ad)Evolus, Inc. Common Stock (EOLS) Stock ForecastsJune 11, 2025 | ca.finance.yahoo.comEvolysse™ Recognized in 2025 Shape Skin AwardsJune 10, 2025 | businesswire.comEvolus Launches CFO Search Ahead of Beaver's ResignationMay 27, 2025 | marketwatch.comEvolus Announces Departure of its Chief Financial OfficerMay 27, 2025 | businesswire.comEvolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid GelsMay 24, 2025 | seekingalpha.comSee More Headlines EOLS Stock Analysis - Frequently Asked Questions How have EOLS shares performed this year? Evolus' stock was trading at $11.04 at the beginning of 2025. Since then, EOLS stock has decreased by 16.0% and is now trading at $9.27. How were Evolus' earnings last quarter? Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings data on Tuesday, March, 23rd. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The business earned $20.58 million during the quarter, compared to the consensus estimate of $20.60 million. Evolus had a negative net margin of 20.40% and a negative trailing twelve-month return on equity of 759.04%. Read the conference call transcript. When did Evolus IPO? Evolus (EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. How do I buy shares of Evolus? Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings3/23/2021Today7/04/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EOLS CIK1570562 Webwww.evolus.com Phone(949) 284-4555FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$23.75 High Stock Price Target$27.00 Low Stock Price Target$21.00 Potential Upside/Downside+156.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$50.42 million Net Margins-20.40% Pretax Margin-20.15% Return on Equity-759.04% Return on Assets-20.14% Debt Debt-to-Equity Ratio22.00 Current Ratio2.34 Quick Ratio2.16 Sales & Book Value Annual Sales$266.27 million Price / Sales2.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book103.00Miscellaneous Outstanding Shares64,480,000Free Float60,672,000Market Cap$597.73 million OptionableOptionable Beta0.97 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:EOLS) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.